Cantor Fitzgerald Issues Negative Forecast for ABOS Earnings

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Equities research analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for shares of Acumen Pharmaceuticals in a report issued on Thursday, May 15th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings per share of ($1.92) for the year, down from their prior forecast of ($1.84). The consensus estimate for Acumen Pharmaceuticals' current full-year earnings is ($1.56) per share.

A number of other equities analysts have also recently commented on ABOS. UBS Group reduced their price objective on shares of Acumen Pharmaceuticals from $6.00 to $4.00 and set a "buy" rating for the company in a research report on Friday, March 28th. HC Wainwright reduced their target price on shares of Acumen Pharmaceuticals from $15.00 to $11.00 and set a "buy" rating for the company in a report on Friday, March 28th.

Acumen Pharmaceuticals Stock Performance

Shares of ABOS stock traded down $0.01 during trading on Monday, reaching $1.03. 450,599 shares of the company's stock were exchanged, compared to its average volume of 292,214. Acumen Pharmaceuticals has a twelve month low of $0.86 and a twelve month high of $3.90. The firm's fifty day moving average price is $1.07 and its 200-day moving average price is $1.57. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $62.39 million, a PE ratio of -0.75 and a beta of 0.09.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.08. During the same period in the prior year, the business posted ($0.25) earnings per share.

Institutional Trading of Acumen Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC increased its holdings in shares of Acumen Pharmaceuticals by 44.2% during the fourth quarter. SG Americas Securities LLC now owns 25,631 shares of the company's stock worth $44,000 after purchasing an additional 7,859 shares during the period. Barclays PLC raised its stake in Acumen Pharmaceuticals by 189.1% in the third quarter. Barclays PLC now owns 61,997 shares of the company's stock valued at $154,000 after purchasing an additional 40,551 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Acumen Pharmaceuticals by 252.8% during the third quarter. JPMorgan Chase & Co. now owns 63,066 shares of the company's stock worth $156,000 after purchasing an additional 45,189 shares during the period. Tower Research Capital LLC TRC grew its stake in Acumen Pharmaceuticals by 427.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 20,624 shares of the company's stock worth $35,000 after buying an additional 16,714 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Acumen Pharmaceuticals by 73.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 98,016 shares of the company's stock worth $169,000 after buying an additional 41,460 shares in the last quarter. Institutional investors own 71.01% of the company's stock.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.